Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Genewiz's Cancer Panels; Gene by Gene's DNA DTC; Verinata's Verifi; COSMIC

Premium

Genewiz is now offering Illumina's TruSeq Cancer Panel and Life Technologies' Ion AmpliSeq Cancer Panel on the MiSeq and PGM, respectively. Additionally, the company is offering custom designed cancer panels.


Gene by Gene has launched DNA DTC, a division that will provide genomic services, including next-generation sequencing, directly to consumers for research-use only.

Its services include 80x exome sequencing on the Illumina HiSeq 2000 at an introductory price of $695; 30x whole-genome sequencing on the HiSeq for $5,495, with a minimum required order of three samples; and 2000x mitochondrial sequencing on the MiSeq for $995. The introductory prices expire at the end of the year. Turnaround times are 6 to 8 weeks for the mitochondrial sequencing and 8 to 10 weeks for the exome and whole-genome sequencing service. The company does not provide interpretation or analysis.


Verinata Health has expanded its Verifi test for trisomy 21, 18, and 13 detection, to include common fetal sex chromosome abnormalities — Turner syndrome, Triple X (XXX), Klinefelter syndrome (XXY) and Jacob's syndrome (XYY).


The Wellcome Trust Sanger Institute has released version 62 of COSMIC, the Catalog of Somatic Mutations in Cancer. The latest release includes the full curation of genes H3F3A, BCOR and HIST1H3B, together with RSPO2/3 fusions in colon cancer and NTRK1 fusions in thyroid cancer. Additionally, 1,068 whole genomes are included from recent TCGA releases.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more